Introduction
The global targeted DNA RNA sequencing market size is expected to reach USD 70.79 billion by 2034, exhibiting a CAGR of 19.4% during 2025–2034.
Targeted DNA and RNA sequencing has revolutionized the field of genomics by providing precise, cost-effective, and efficient methods for studying genetic materials. This advanced sequencing approach focuses on specific regions of DNA or RNA, offering critical insights into gene expression, mutations, and structural variations. The targeted DNA/RNA sequencing market has witnessed substantial growth due to its applications in personalized medicine, diagnostics, and biopharmaceutical research.
Market Overview
The targeted DNA/RNA sequencing market encompasses a wide range of applications, including oncology, infectious diseases, and genetic disorders. This market is driven by the increasing demand for next-generation sequencing (NGS) technologies, which offer high throughput and sensitivity. Major players in the market provide innovative solutions that cater to academic research, clinical diagnostics, and drug discovery.
Download Free Sample PDF Copy of the Report:
Key Companies in the Targeted DNA RNA Sequencing Market
- Illumina Inc.
- Thermo Fisher Scientific
- Agilent Technologies
- Roche Sequencing Solutions
- QIAGEN
- Pacific Biosciences
- Oxford Nanopore Technologies
- BGI Genomics
- Genomatix Software
- Bio-Rad Laboratories
- PerkinElmer
- Hudon Alpha
- Element Biosciences
- Twist Bioscience
- Nextera
Key Market Segments
The research report categorizes the market into various segments and sub-segments. The primary segments covered in the study include type, method, end use, workflow. The splitting of the market into various groups enables businesses to understand market preferences and trends better
Targeted DNA RNA Sequencing Market, Type Outlook (Revenue – USD Billion, 2020-2034)
- RNA-Based
- DNA-Based
Targeted DNA RNA Sequencing Market, Method Outlook (Revenue – USD Billion, 2020-2034)
- Exome Sequencing
- Enrichment Sequencing
- Amplicon Sequencing
- Others
Targeted DNA RNA Sequencing Market, End User Outlook (Revenue – USD Billion, 2020-2034)
- Academic Research
- Hospitals & Clinics
- Pharma & Biotech Entities
- Others
Targeted DNA RNA Sequencing Market, Workflow Outlook (Revenue – USD Billion, 2020-2034)
- Pre-sequencing
- Sequencing
- Data Analysis
Market Growth Drivers
The targeted DNA/RNA sequencing market is driven by various factors, including:
3.1 Rising Prevalence of Chronic Diseases
With the global rise in cancer, cardiovascular diseases, and genetic disorders, the demand for precise diagnostic tools like targeted sequencing is increasing.
3.2 Advancements in NGS Technologies
Rapid advancements in NGS platforms, coupled with declining sequencing costs, have made targeted DNA/RNA sequencing more accessible and efficient.
3.3 Growth of Personalized Medicine
The increasing focus on personalized medicine, which tailors treatments based on an individual’s genetic makeup, has significantly boosted the demand for targeted sequencing technologies.
3.4 Government and Private Funding
Substantial investments in genomics research and the establishment of sequencing centers globally have further propelled market growth.
Key Trends in the Market
The targeted DNA/RNA sequencing market is witnessing several trends that shape its trajectory:
4.1 Integration of Artificial Intelligence (AI)
AI and machine learning are being incorporated into sequencing workflows to enhance data analysis, interpretation, and predictive modeling.
4.2 Adoption of Liquid Biopsy
Targeted sequencing is increasingly being used in liquid biopsy applications, offering non-invasive diagnostic options.
4.3 Expansion of Applications Beyond Oncology
While oncology remains a primary focus, targeted sequencing is gaining traction in neurology, cardiology, and infectious disease research.
4.4 Emphasis on Data Security
As sequencing generates large volumes of sensitive data, companies are focusing on enhancing data security and compliance with global regulations.
Research Scope
The research scope for targeted DNA/RNA sequencing is vast, encompassing innovations in technology, applications, and methodologies:
5.1 Development of Ultra-High-Throughput Platforms
Future research is aimed at developing platforms with even higher throughput capabilities for large-scale studies.
5.2 Epigenetics and Transcriptomics
The integration of targeted sequencing with epigenetics and transcriptomics research is expanding the scope of genetic studies.
5.3 Collaborative Research Initiatives
Collaborations between academic institutions, biopharma companies, and sequencing technology providers are fostering innovation and new product development.
Future Outlook
The targeted DNA/RNA sequencing market is poised for significant growth in the coming years, driven by technological advancements and expanding applications. Key projections include:
- Market Growth: The market is expected to grow at a robust CAGR, with increasing adoption in emerging economies.
- Technological Innovations: Continuous R&D will lead to the development of more accurate, faster, and cost-effective sequencing solutions.
- Expansion in Healthcare: Targeted sequencing will play a critical role in shaping the future of precision medicine and genomic diagnostics.
Recent Developments in the Targeted DNA and RNA Sequencing Market
August 2024: Thermo Fisher Scientific introduced the InnoviGene Suite, an all-in-one, browser-based platform designed to streamline data analysis and enhance the interpretation of Sanger sequencing results. This suite offers customizable reports and advanced AI-based basecalling, aiming to improve clarity and relevance in genomic research and clinical diagnostics.
July 2024: Illumina launched the NovaSeq 6000Dx, the first FDA-registered and CE-marked in vitro diagnostic high-throughput sequencer. This instrument delivers high compliance standards and actionable insights for patient care, expanding the breadth of applications and clinical testing in regions requiring IVD products.
These advancements reflect the industry’s commitment to enhancing sequencing technologies, providing researchers and clinicians with more efficient and accurate tools for genomic analysis.
The global targeted DNA/RNA sequencing market focuses on sequencing specific regions of DNA or RNA to analyze genetic variations associated with various diseases and conditions.